$EXEL News

Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals

BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

Exelixis (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot

Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52

Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating

Stifel Maintains Hold on Exelixis, Raises Price Target to $51

Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...

Exelixis Q2 Earnings Call Highlights

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered

Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings

Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est

Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate

Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $53

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026